Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress (GlobeNewswire) - Oct 19, 2022 - P1 | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics "Plus Therapeutics, Inc...presented data from two ongoing clinical trials evaluating the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM) at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM)....All four patients treated to date in Cohorts 1 and 2 were observed to have prompt and complete 186RNL distribution throughout the cerebrospinal fluid (CSF) subarachnoid space that was durable past 28 days and was well tolerated. All patients showed a decreased CSF cell count by microfluidic chamber assay after treatment, ranging from 46% to 92%. Cohort 2 in the ReSPECT-LM trial has commenced, with interim data from the first two patient cohorts expected by the end of 2022."
P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|